Literature DB >> 11831094

Advances in the treatment of soft-tissue sarcomas.

Celia Chao1, Kelly M McMasters, Michael J Edwards.   

Abstract

Over 8000 newly diagnosed cases of sarcoma will occur in the United States this year. The family practitioner will encounter many soft-tissue masses, and the great majority of such masses will be benign. The clinician should maintain a high index of suspicion for lesions 5 cm or larger. Tissue diagnosis as well as accurate staging are important for optimal management. Limb salvage and improved prognosis are possible with the use of multimodality techniques. The goal in the overall management of soft-tissue sarcomas is a curative, yet functional, outcome. Adjuvant brachytherapy may be advantageous for patients who require but who are unable to receive daily external beam radiation. Treatment options, including some with targeted molecular therapies, are in the forefront of ongoing research.

Entities:  

Mesh:

Year:  2002        PMID: 11831094

Source DB:  PubMed          Journal:  J Ky Med Assoc        ISSN: 0023-0294


  4 in total

1.  [Soft tissue sarcoma of the upper extremities. Analysis of factors relevant for prognosis in 160 patients].

Authors:  M Lehnhardt; C Hirche; A Daigeler; O Goertz; A Ring; T Hirsch; D Drücke; J Hauser; H U Steinau
Journal:  Chirurg       Date:  2012-02       Impact factor: 0.955

2.  Suppression of soft tissue sarcoma growth by a host defense-like lytic peptide.

Authors:  Lars Steinstraesser; Jennifer Hauk; Cornelius Schubert; Sammy Al-Benna; Ingo Stricker; Hanns Hatt; Yechiel Shai; Hans-Ulrich Steinau; Frank Jacobsen
Journal:  PLoS One       Date:  2011-03-31       Impact factor: 3.240

3.  Feasibility of chemosensitivity testing in soft tissue sarcomas.

Authors:  Marcus Lehnhardt; Thomas Muehlberger; Cornelius Kuhnen; Daniel Brett; Hans U Steinau; Hamid Joneidi Jafari; Lars Steinstraesser; Oliver Müller; Heinz H Homann
Journal:  World J Surg Oncol       Date:  2005-04-18       Impact factor: 2.754

4.  Response rate of fibrosarcoma cells to cytotoxic drugs on the expression level correlates to the therapeutic response rate of fibrosarcomas and is mediated by regulation of apoptotic pathways.

Authors:  Marcus Lehnhardt; Ludger Klein-Hitpass; Cornelius Kuhnen; Heinz Herbert Homann; Adrien Daigeler; Hans Ulrich Steinau; Sonja Roehrs; Laura Schnoor; Lars Steinstraesser; Oliver Mueller
Journal:  BMC Cancer       Date:  2005-07-07       Impact factor: 4.430

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.